The selective disruption of protein-protein interactions holds potential for new drug discovery strategies. Dr Katherine Bridge is a Research Fellow at the University of York investigating the role of…
Rapid and reversible aptamer binding is helping to build new in vivo biosensors that will change the way we diagnose and treat disease. Dr Netz Arroyo is an Assistant Professor…
Life at Aptamer Group and top tips for success in Optimer binder development In this interview, we speak with Harriet Flynn, Production Manager at Aptamer Group. From starting as…
Toni Rogers and David Bunka of Aptamer Group examine the latest tools and assays to address small molecule targets and deliver faster, cheaper and better diagnostics in this feature…
The reproducible performance and wide target range of aptamers are enabling researchers of all levels in the pursuit of better diagnostics. Dr Mark Platt at…
Novel diagnostic platforms are bringing possibilities for improved patient care and reduced healthcare costs. We spoke with Dr Edgar Goluch, the CEO and founder of QSM Diagnostics,
The use of antibody-drug conjugates has become particularly prevalent in cancer therapy, although their development can be problematic in their execution. However, aptamers can be used as…
